Novo Nordisk and Potential Trump Tariffs | Global Banking & Finance Review | GBAF

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Headlines > Novo Nordisk says it's not immune to potential Trump tariffs, but business is well-positioned

Headlines

Novo Nordisk says it's not immune to potential Trump tariffs, but business is well-positioned

Published by Global Banking and Finance Review

Posted on February 5, 2025

1 min read

Last updated: January 26, 2026

Novo Nordisk CEO Lars Fruergaard Jorgensen discussing tariff impacts - Global Banking & Finance Review — Novo Nordisk CEO Lars Fruergaard Jorgensen addresses potential tariffs from Trump and their impact on the company, showcasing confidence in business positioning amid economic challenges.

Quick Summary

Novo Nordisk may face tariffs from Trump's EU policies, but CEO Lars Fruergaard Jorgensen remains confident in the company's strong market position.

Novo Nordisk Faces Potential Tariffs, Stays Confident

LONDON (Reuters) - Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, its chief executive said on Wednesday, but it is confident its business is well-positioned.

Novo Nordisk CEO Lars Fruergaard Jorgensen was speaking to journalists at the company's headquarters just outside Copenhagen after the company reported fourth-quarter earnings.

(Reporting by Maggie Fick; Editing by Emelia Sithole-Matarise)

Key Takeaways

•Novo Nordisk may be affected by Trump's EU tariffs.
•CEO Lars Fruergaard Jorgensen remains confident in business positioning.
•The company reported its fourth-quarter earnings.
•The announcement was made at the Copenhagen headquarters.
•Tariffs could impact the pharmaceutical industry.

Frequently Asked Questions about Novo Nordisk says it's not immune to potential Trump tariffs, but business is well-positioned

1What is the main topic?

The article discusses Novo Nordisk's potential exposure to tariffs imposed by the Trump administration on the EU and its business outlook.

2How is Novo Nordisk responding to the tariff threat?

Novo Nordisk's CEO expressed confidence in the company's business positioning despite the potential tariffs.

3Where did the CEO make the announcement?

The announcement was made at Novo Nordisk's headquarters near Copenhagen.